Back to search resultsSummaryRMgm-1100
|
||||||||
*RMgm-1100| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene disruption |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 25032958 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | P. berghei ANKA 2.34 |
| Other information parent line | P. berghei ANKA GFP-con clone 2.3.4 |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Oppenheim, RD; Soldati-Favre, D |
| Name Group/Department | Department of Microbiology and Molecular Medicine, Faculty of Medicine |
| Name Institute | University of Geneva |
| City | Geneva |
| Country | Switzerland |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-1100 |
| Principal name | Pbe1a_ko |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Strongly reduced growth of asexual blood stages. Evidence is presented that parasites can only develop into mature schizonts in reticulocytes and not in normocytes |
| Gametocyte/Gamete | Lower production of male and female gametocytes. Reduced exflagellation of male gametocytes. |
| Fertilization and ookinete | Lower production of male and female gametocytes. Reduced exflagellation of male gametocytes. Reduced ookinete production |
| Oocyst | Reduced ookinete production Reduced oocyst production Aberrant formation of oocysts: reduced size and absence of sporogony (sporozoite formation) |
| Sporozoite | Reduced ookinete production Reduced oocyst production Aberrant formation of oocysts: reduced size and absence of sporogony (sporozoite formation) Absence of salivary gland sporozoites |
| Liver stage | Not tested |
| Additional remarks phenotype | Mutant/mutation |
Disrupted: Mutant parasite with a disrupted gene| top of page | |||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_1411100 | ||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_1312600 | ||||||||||||||||||||||||
| Gene product | 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial, putative | ||||||||||||||||||||||||
| Gene product: Alternative name | BCKDHA; BCKDH-E1a | ||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||
| Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||
| Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
| Additional remarks partial/complete disruption | |||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||
| Additional remarks genetic modification | |||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||
|
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||